9.5mg/ml
Trade Name
Livmarli
Oral solution
Request Type
Registration
Drug Type
NCE
Approval Date
SFDA Approved Use
Maralixibat is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 3 months of age and older